sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Safinamide

Medicine

Safinamide

XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.
Do not take if
  • Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid. The combination may result in increased blood pressure, including hypertensive crisis.
  • Concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol); serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic, tetracyclic, or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate, amphetamine, and their derivatives; or St John's wort. Concomitant use could result in life-threatening serotonin syndrome.
  • Concomitant use of dextromethorphan. The combination of MAOIs and dextromethorphan has been reported to cause episodes of psychosis or abnormal behavior.
  • A history of a hypersensitivity to safinamide. Reactions have included swelling of the tongue and oral mucosa, and dyspnea.

Side effects, and when to stop

The following serious adverse reactions are discussed in greater detail in other sections of labeling:

  • Hypertension
  • Serotonin Syndrome
  • Falling Asleep During Activities of Daily Living
  • Dyskinesia
  • Hallucinations / Psychotic Behavior
  • Impulse Control / Compulsive Behaviors
  • Withdrawal-Emergent Hyperpyrexia and Confusion
  • Retinal Pathology

Who should not take it

XADAGO is contraindicated in patients with:

  • Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid. The combination may result in increased blood pressure, including hypertensive crisis.
  • Concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol); serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic, tetracyclic, or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate, amphetamine, and their derivatives; or St John's wort. Concomitant use could result in life-threatening serotonin syndrome.
  • Concomitant use of dextromethorphan. The combination of MAOIs and dextromethorphan has been reported to cause episodes of psychosis or abnormal behavior.
  • A history of a hypersensitivity to safinamide. Reactions have included swelling of the tongue and oral mucosa, and dyspnea.
  • Severe hepatic impairment (Child-Pugh C: 10-15).

Storing it

Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Safinamide; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/safinamide

APA 7th

sofidex. (2026, August 3). Safinamide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/safinamide

AMA 11th

Safinamide. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/safinamide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.